H.pylori
Conditions
Interventions
Control group: Esomeprazole 20mg qid + Amoxicillin 750mg qid
Test group 1:Esomeprazole 40mg bid + Amoxicillin 1000mg tid
Test group 2:Esomeprazole 20mg tid + Amoxicillin 1000mg tid
Sponsors
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Adult patients, aged between 18-65 years; 2.Patients diagnosed as HP infection by C13 / C14 urea breath test or immunohistochemical staining of biopsy samples; 3.Patients with indications of HP eradication and no antagonistic factors; 4.Patients who have not received HP eradication treatment before; 5.Patients who did not take antibiotics, bismuth and antibacterial traditional Chinese medicine 4 weeks before the treatment, and those who did not take PPI, H2 receptor antagonists and other drugs that affect the activity of HP 2 weeks before the treatment; 6.Patients were informed and agreed to participate in the study.
Exclusion criteria
Exclusion criteria: 1.Patients with severe heart, liver, lung and kidney dysfunction and low immunity; 2.Patients with penicillin or program related drug allergy contraindications; 3.Patients with mental illness and communication disorder; 4.Pregnant and lactating patients; 5.Patients with organic diseases such as gastrointestinal tumor and gastrointestinal hemorrhage; 6.Patients who are participating in other clinical trials; 7.The researchers think it is not suitable for the patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events;Compliance; | — |
Countries
China
Contacts
Public ContactLi Peiyuan
Division of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed